Abstract: Various therapeutic polynucleotides are provided along with their use to treat a variety of disease states. The chimeric polynucleotides disclosed herein comprise an OPN aptamer linked to an OPN-specific therapeutic oligonucleotide in order to deliver the OPN-specific therapeutic polynucleotide to the site of OPN expression. Thus, the specificity of OPN aptamers allows delivery of therapeutic molecules to the site of unhealthy tissue. Accordingly, the chimeric polynucleotides disclosed herein can reduce at least one symptom of a disease or unhealthy condition by delivering an OPN-specific therapeutic oligonucleotide that interferes with a disease promoting factor.

Abstract: MicroRNA molecules are directed to the treatment of diseases associated with plaque formation, cardiovascular diseases, inflammation, stroke, and disorders associated with aging.

Abstract: Compositions, kits, cells and methods for treating cardiovascular (e.g., myocardial ischemia and heart failure), immunological, and inflammatory diseases or disorders involve the use of the mature and precursor sequences of microRNAs 142-5p, 142-3p, 17-5p, 17-3p, 374, and 20a, and of antisense molecules complementary to these sequences, to manipulate processes relevant to, for example, the cardiac response to stress, including survival signaling, angiogenesis, stem cell differentiation along muscle or vascular lineages, and repression or promotion of cardiac myocyte growth. Also described are methods to treat cardiovascular, immunological and inflammatory diseases by engineering cells containing specific micro-RNAs or antagomirs against specific mRNAs. The engineered cells can then be used to treat patients with such diseases by autologous stem cell therapy.

Abstract: MicroRNA molecules are directed to the treatment of diseases associated with plaque formation, cardiovascular diseases, inflammation, stroke, and disorders associated with aging.

Abstract: Models of different patterns of genetic interactions were formulated and used in methods to determine the architecture of genetic interactions from mRNA expression levels measured in microarray experiments. The methods can be used to screen biological systems to identify which systems are candidates for therapeutic intervention. Also provided are machine readable storage and systems for using the disclosed models and methods.